Sign In
Buy ERAS
$13.67
-0.310 (-2.22%)
At Close: Jun 18, 2026
Erasca Announces Three Poster Presentations at the 2025 AACR Annual Meeting
04:31pm, Tuesday, 25'th Mar 2025
Presentations will feature potential best-in-class pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001 Erasca will also present potential first-in-class examples of direct SMP complex in
Erasca Reports Fourth Quarter and Full Year 2024 Business Updates and Financial Results
04:01pm, Thursday, 20'th Mar 2025
Potentially best-in-class RAS-targeting franchise advancing with both ERAS-0015 and ERAS-4001 expected to enter the clinic in 2025
Erasca to Present at the Guggenheim Securities SMID Cap Biotech Conference
08:00am, Friday, 31'st Jan 2025
SAN DIEGO, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for
Erasca's Naporafenib Is Shaping Up Nicely For NRASm Melanoma
12:09am, Monday, 27'th Jan 2025
Naporafenib is Erasca's main candidate, and it has Fast Track status for NRASm melanoma. I see the company has a robust balance sheet, with roughly $463.3 million in cash and equivalents as of Q3, 202
Down -25.4% in 4 Weeks, Here's Why You Should You Buy the Dip in Erasca (ERAS)
10:36am, Tuesday, 21'st Jan 2025
Erasca (ERAS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates co
Down -27.17% in 4 Weeks, Here's Why Erasca (ERAS) Looks Ripe for a Turnaround
10:40am, Monday, 20'th Jan 2025
Erasca (ERAS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising ea
Down -24.08% in 4 Weeks, Here's Why You Should You Buy the Dip in Erasca (ERAS)
10:35am, Friday, 17'th Jan 2025
Erasca (ERAS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates co
Down -22.89% in 4 Weeks, Here's Why You Should You Buy the Dip in Erasca (ERAS)
10:35am, Thursday, 16'th Jan 2025
Erasca (ERAS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising ea
Erasca (ERAS) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
11:00am, Friday, 15'th Nov 2024
After losing some value lately, a hammer chart pattern has been formed for Erasca (ERAS), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revision
Erasca Reports Third Quarter 2024 Business Updates and Financial Results
04:01pm, Tuesday, 12'th Nov 2024
Positive preliminary Phase 1b data in SEACRAFT-1 NRASm melanoma cohort bolsters conviction in ongoing SEACRAFT-2 registrational trial; Stage 1 randomized data expected in 2025
Erasca to Present at Upcoming Investor Conferences
08:00am, Tuesday, 05'th Nov 2024
SAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for
Erasca Reports Second Quarter 2024 Business Updates and Financial Results
04:01pm, Monday, 12'th Aug 2024
In-licensed potential best-in-class pan-RAS molecular glue ERAS-0015 and potential first-in-class pan-KRAS inhibitor ERAS-4001 with a goal of expanding treatment options across RAS-driven tumors
Should You Buy Erasca, Inc. (ERAS) After Golden Cross?
10:56am, Tuesday, 04'th Jun 2024
After reaching an important support level, Erasca, Inc. (ERAS) could be a good stock pick from a technical perspective. ERAS recently experienced a "golden cross" event, which saw its 50-day simple mo
Erasca to Present at Upcoming Investor Conferences in June
08:00am, Wednesday, 29'th May 2024
SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for p
SAN DIEGO, May 21, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for pa
